Access
To read this story in full you will need to login or make a payment (see right).
Letters to Nature
Nature 309, 163-165 (10 May 1984) | doi:10.1038/309163a0; Accepted 21 March 1984
Atypical
-adrenoceptor on brown adipocytes as target for anti-obesity drugs
J. R. S. Arch, A. T. Ainsworth, M. A. Cawthorne, V. Piercy, M. V. Sennitt, V. E. Thody, C. Wilson & S. Wilson
- Beecham Pharmaceuticals, Biosciences Research Centre, Great Burgh, Yew Tree Bottom Road, Epsom, Surrey KT18 5XQ, UK
Abstract
Recent studies suggest that thermogenesis in brown adipose tissue has an important role in the regulation of energy balance1–7. Thermogenesis is effected by noradrenaline released from sympathetic nerve endings; the noradrenaline stimulates
;-adrenoceptors, causing lipolysis, and the released fatty acids then promote the uncoupling of oxidative phosphorylation from electron transport8,9. It has been widely accepted10–13 that mammalian
-adrenoceptors exist as two subtypes,
1 and
2 (ref. 14), and rat brown adipocyte
-adrenoceptors have been classed as
1 (refs 15–17) or as a mixed
1/
2 population18. The
1 subtype predominates in atria, whereas the
2 subtype predominates in trachea. However, we have now found a novel group of
-adrenoceptor agonists that selectively stimulate lipolysis in brown adipocytes. In contrast, isoprenaline, fenoterol and salbutamol are less potent as stimulants of lipolysis than as stimulants of atrial rate or tracheal relaxation. Therefore,
-adrenoceptors in rat brown adipocytes are of neither the
1 nor
2 subtypes. Compounds that selectively stimulate brown adipocyte
-adrenoceptors should have potential as thermogenic anti-obesity agents and this has been demonstrated with BRL 26830A, BRL 33725A and BRL 35135A.
To read this story in full you will need to login or make a payment (see right).
